FDA waves Epizyme's $186K rare can­cer drug through to mar­ket — now get ready for the sec­ond act

Af­ter win­ning the hearts of the ex­pert pan­el con­vened by the FDA de­spite a bleak in-house re­view and a check­ered de­vel­op­ment his­to­ry, Robert Baze­more has steered Epizyme to its first-ever OK for a rare can­cer drug.

The ap­proval in ep­ithe­lioid sar­co­ma sets tazeme­to­stat, now Tazverik, up nice­ly for a quick ex­pan­sion to fol­lic­u­lar lym­phoma — a much big­ger in­di­ca­tion for which the biotech has just sub­mit­ted an NDA.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER